Ajax...In our numerous conversations you've always had a primary suspect that "organized" the delay of exclusivity...turns out you where right IMO. Doesn't surprise me you had the answer a year ahead of me.
As the World knows, GSK has/had an active mechanism of bribery in China, DO THEY HAVE THIS SAME MECHANISM IN PLACE AT THE FDA?
BB
United States Patent 8,871,800
Rongen , et al. October 28, 2014
Statin and omega-3 fatty acids for reduction of Apo-B levels
Abstract
Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.
Inventors: Rongen; Roelof M. L. (Califon, NJ), Shalwitz; Robert A. (Bexley, OH), Kling; Douglas (Parsippany, NJ), Doyle, Jr.; Ralph T. (Milford, NJ)
Applicant:
Name City State Country Type
Rongen; Roelof M. L.
Shalwitz; Robert A.
Kling; Douglas
Doyle, Jr.; Ralph T.
Califon
Bexley
Parsippany
Milford
NJ
OH
NJ
NJ
US
US
US
US
Assignee: GlaxoSmithKline, LLC (Wilmington, DE)
Family ID: 46329290
Appl. No.: 12/561,558
Filed: September 17, 2009
News 
Market Data 
Discover 
